AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Explore various resources to find financial education workshops in your area. Enhance your financial literacy and skills.
17,041 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
A top executive recently moved a sizable block of Impinj stock. This article unpacks why insider sales happen, how to...
When Goldman Sachs raises its dividend as advisory and underwriting fees rebound, investors take notice. This article...
A seven-year high in regional bank M&A signals bigger players aiming for scale and efficiency. This guide breaks down...
A routine drive-thru moment can turn into a wallet scare. This article explains how card fraud can occur in drive-thr...
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
Investors are increasingly favoring dividend growth over high yields, signaling a shift toward smaller dividends that...
As the cost of nursing-home care climbs past six figures annually, medicare won’t touch long-term care costs, forcing...
Retirees face roughly $36,000 per year in aging-in-place costs, rising faster than Social Security. A carefully craft...
Robinhood accelerates its blockchain push to compete with Coinbase, while Base narrows its focus to trading, payments...
Copart director Daniel Englander recently sold 80,000 shares for about $2.2 million. With CPRT down roughly 40%, inve...
Want crypto exposure without sacrificing diversification? This guide shows how crypto etfs part diversified fits into...